Skip to main content
. 2019 Jan-Mar;12(1):63–67. doi: 10.4103/JCAS.JCAS_40_18

Figure 5.

Figure 5

Erythema, telangiectasia, and acneiform eruptions secondary to HQ use: (A) at baseline and (B) after 4 weeks of HQ